Skip navigation

UCB SA

Pharmaceuticals
Belgium
2016 Revenue (US$ Millions)$4,411
Revenue Growth (%)7.79%
Net Income (US$ Millions)$549
Earnings Per Share (US$)$2.91
EPS Growth Rate (%)-15.08%
Profit Margin12.45%
Total Equity (US$ Millions)$5,896
Return on Equity (%)9.17%
Long Term Debt (US$ Millions)$1,662
Debt To Equity Ratio (%)0.28%
Total Assets (US$ Millions)$10,783
Current Assets (US$ Millions)$2,461
Current Liabilities (US$ Millions)$2,553
Cost of Goods Sold (US$ Millions)$1,269
Inventory Turnover2.10